Table 1. Sample study characteristics.
| Study title | Absorb II | Absorb III | Absorb China | Absorb Japan | Trofi II | Everbio II | AIDA | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General study characteristics | ||||||||||||||||
| Population | 501 | 2008 | 475 | 400 | 191 | 158 | 1845 | |||||||||
| Follow-up | 3 years | 2 years | 1 years | 1 years | 6 months | 9 months | 2 years | |||||||||
| Group | DES | BVS | DES | BVS | DES | BVS | DES | BVS | DES | BVS | DES | BVS | DES | BVS | ||
| No. of patients | 335 | 166 | 1,322 | 686 | 238 | 237 | 134 | 266 | 191 | 96 | 80 | 78 | 921 | 924 | ||
| CV risk factors | ||||||||||||||||
| Age (mean ± SD) | 61.5 (±10) | 60.9 (±10) | 63.5 (±10.6) | 63.6 (±10.3) | 57.2 (±11.4) | 57.7 (±9.6) | 67.1 (±9.4) | 67.3 (±9.6) | 59.1 (±10.7) | 58.2 (±9.6) | 65 (±11) | 65 (±11) | 64 (±10.5) | 64.3 (±10.6) | ||
| Male [%] | 253 [76] | 132 [79] | 934 [70] | 481 [70] | 171 [71] | 172 [73] | 99 [74] | 210 [79] | 147 [77] | 84 [88] | 64 [80] | 61 [78] | 700 [76] | 670 [72] | ||
| Smoking habits [%] | 79 [23] | 80 [48] | 281 [21] | 142 [20] | 78 [33] | 84 [35] | 29 [21] | 53 [20] | 22 [23] | 47 [50] | 30 [38] | 28 [36] | 273 [32] | 248 [29] | ||
| Diabetes [%] | 22 [7] | 40 [24] | 416 [31] | 224 [32] | 60 [25] | 55 [23] | 48 [36] | 96 [36] | 18 [19] | 14 [15] | 13 [16] | 17 [22] | 153 [17] | 171 [18] | ||
| Hypertension [%] | 231 [69] | 119 [71] | 1,122 [85] | 583 [85] | 140 [59] | 143 [60] | 107 [80] | 208 [78] | 41 [44] | 35 [37] | 51 [64] | 78 [43] | 464 [51] | 468 [51] | ||
| Dyslipidaemia [%] | 252 [75] | 133 [80] | 1,140 [86] | 592 [86] | 101 [42] | 91 [38] | 110 [82] | 218 [82] | 60 [64] | 55 [57] | 50 [63] | 44 [56] | 350 [38] | 344 [38] | ||
| Previous MI [%] | 48 [14] | 93 [56] | 150 [22] | 282 [21] | 38 [16] | 40 [17] | 32 [23] | 42 [16] | 3 [3] | 2 [2] | 14 [18] | 11 [14] | 172 [19] | 166 [18] | ||
| Previous PCI [%] | 5 [1] | 14 [8] | / | / | 19 [8] | 23 [10] | 7 [5] | 9 [3] | 3 [3] | 4 [4] | 25 [32] | 25 [31] | 184 [20] | 202 [22] | ||
| Coronary lesion | ||||||||||||||||
| LAD [%] | 84 [46] | 163 [45] | 301 [42] | 617 [45] | 132 [52] | 139 [55] | 58 [46) | 127 [46] | 44 [45] | 44 [46] | 78 [34] | 44 [46] | 528 [44] | 526 [42] | ||
| CX [%] | 42 [23] | 106 [29] | 218 [31] | 363 [26] | 61 [24] | 49 [20] | 36 [26) | 63 [23] | 41 [42] | 34 [36] | 21 [19] | 24 [25] | 318 [26] | 298 [24] | ||
| RCA [%] | 56 [31] | 95 [26] | 194 [27] | 404 [29] | 59 [23] | 63 [25] | 43 [31) | 85 [31] | 13 [13] | 17 [18] | 40 [36] | 24 [25] | 348 [29] | 401 [32] | ||
| Clinical presentation | ||||||||||||||||
| STEMI [%] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 96 [100] | 95 [100] | 6 [8] | 9 [12] | 225 [24] | 240 [26] | ||
| NSTEMI [%] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 16 [20] | 13 [17] | 192 [21] | 185 [20] | ||
| UA [%] | 37 [22] | 68 [30] | 168 [25] | 355 [27] | 152 [64] | 154 [65] | 22 [16] | 26 [10] | 0 [0] | 0 [0] | 5 [6] | 6 [8] | 87 [9] | 70 [8] | ||
| SCAD [%] | 107 [64] | 214 [64] | 417 [61] | 757 [57] | 50 [17] | 53 [22] | 88 [66] | 170 [64] | 0 [0] | 0 [0] | 47 [59] | 41 [53] | 370 [40] | 361 [39] | ||
| SI [%] | 19 [11] | 42 [13] | 70 [10] | 132 [10] | 13 [6] | 9 [4] | 24 [18] | 70 [26] | 0 [0] | 0 [0] | 6 [8] | 9 [12] | ||||
DES, drug eluting stents; BVS, bioresorbable vascular scaffold; SI, silent ischemia; STEMI, ST elevation myocardial infarction; NSTEMI, non ST elevation myocardial infarction; UA, unstable angina; SCAD, stable coronary artery disease; RCA, right coronary artery; CX, circumflex artery; LAD, left anterior descendent artery; MI, myocardial infarction; PCI, percutaneous coronary intervention; CV, cardiovascular; SD, standard deviation.